Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs

 
• By Brenda Sandburg

GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.

Expanded access
Biopharma companies describe challenges in expanding access to investigational drugs • Source: Shutterstock

More from R&D

More from Pink Sheet